IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Ieq Capital LLC

Ieq Capital LLC cut its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 18,925 shares of the medical research company’s stock after selling 241 shares during the quarter. Ieq Capital LLC’s holdings in IQVIA were worth $4,001,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of IQV. Versant Capital Management Inc grew its holdings in IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares during the period. Opal Wealth Advisors LLC bought a new position in shares of IQVIA during the 2nd quarter valued at about $27,000. Rise Advisors LLC acquired a new position in shares of IQVIA in the 1st quarter worth approximately $31,000. Riverview Trust Co bought a new stake in shares of IQVIA in the 1st quarter worth approximately $32,000. Finally, International Assets Investment Management LLC acquired a new stake in IQVIA during the second quarter valued at approximately $32,000. Institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

IQV has been the topic of several recent research reports. JPMorgan Chase & Co. lifted their price target on shares of IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a research report on Monday, August 5th. Royal Bank of Canada began coverage on IQVIA in a research report on Wednesday, September 4th. They set an “outperform” rating and a $275.00 target price on the stock. Morgan Stanley upped their target price on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. Argus raised IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Finally, StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Thursday, September 5th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $267.00.

IQVIA Trading Down 1.0 %

IQVIA stock opened at $242.24 on Friday. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The company’s fifty day simple moving average is $240.60 and its 200-day simple moving average is $234.19. The stock has a market cap of $44.16 billion, a P/E ratio of 33.09, a P/E/G ratio of 2.25 and a beta of 1.49.

IQVIA (NYSE:IQV) last issued its earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The firm had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. During the same quarter in the previous year, the company posted $2.22 earnings per share. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.